What Goes Around Comes Around: Radiation Therapy of Nonmalignant Disorders

This session provides an overview of radiotherapy for nonmalignant indications from the lead co-editor of the 3rd edition of Radiation Therapy of Benign Diseases. The presentation touches on historical aspects as well as contemporary trends. Following the structure of this textbook, diseases irradiated are categorized as autoimmune, cutaneous, infectious, inflammatory, endocrine, musculoskeletal, neurological, lymphoid, pain-related, psychiatric, reproductive, tumoral, vascular or miscellaneous. The evidence supporting many indications is summarized and tips are shared for estimating treatment toxicity. 

Presenter: David Roberge, MD
Moderator: Arshin Sheybani, MD

This session was originally presented and recorded as a live webinar on August 28, 2024.

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation dosimetrists, and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Classify potential indications for radiotherapy of benign diseases.
  • Identify trends and knowledge gaps in radiotherapy of benign diseases.
  • Estimate the risk of treatment toxicity.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
07/22/2024
Course expires: 
10/09/2026
Cost:
$0.00
Part of: 
Expanding the Scope of Radiation Therapy for Nonmalignant Diseases
Rating: 
0
  • David Roberge, MD is employed by CHUM. Dr. Roberge receives honoraria and travel expenses as an Advisory Board member, consultant, and education/meeting faculty for Novocure; research funding (institution) from Novocure; honoraria and travel expenses as education/meeting faculty for Accuray; honoraria as a consultant and education/meeting faculty for Recordati; honoraria as an Advisory Board member for Roche Canada, Servier Canada, and AstraZeneca Canada. Dr. Roberge has ownership equity/warrants in MISO Chip, Croton Healthcare, and AFX Medical. Dr. Roberge is co-chair of the Brain Disease Site Committee for the Canadian Cancer Trials Group and President-elect of the Canadian Association of Radiation Oncology.
  • Arshin Sheybani, MD is employed by UnityPoint Health. Dr. Sheybani is the community oncologist representative on the National Cancer Institute Gastrointestinal Steering Committee Rectal-Anal Task Force, member of the ASTRO Nominating Committee, and co-PI on an Iowa-Wide Oncology Research Coalition, a National Cancer Institute Community Oncology Research Program.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.